Methods of enhancing functioning of the large intestine

A method for treating a subject to enhance functioning of the large intestine comprising the step of delivering to the large intestine of the subject an effective amount of an intestinotrophic GLP-2 analog of SEQ ID NO:

• 1, wherein
• a) position 2 of the analog is an amino acid other than Ala,
• b) positions 1, 4, 6, 7, 9, 12-15, 17-23, 25-27, and 29-33 of the analog correspond to the amino acids of SEQ ID NO:
• 1;
• c) position 3 of the analog is optionally an amino acid other than Asp, wherein the amino acid other than Asp confers relative resistance to DPP-IV mediated cleavage;
• d) position 5 of the analog is optionally an amino acid other than Ser;
• e) position 8 of the analog is optionally an amino acid other than Asp;
• f) position 10 of the analog is optionally an amino acid other than Met;
• g) position 16 of the analog of SEQ ID NO:
• 1 optionally consists of an amino acid other than Asn;
• and
• h) position 28 of the analog is optionally an amino acid other than Gln.

A method for treating a subject having, or at risk of developing, a condition in which functioning of the large intestine is impaired to enhance functioning of the large intestine comprising the steps of:

• a) obtaining an intestinotrophic GLP-2 analog of SEQ ID NO:
• 1, wherein
• i. position 2 of the analog is an amino acid other than Ala;
• ii. positions 1, 4, 6, 7, 9, 12-15, 17-23, 25-27, and 29-33 of the analog correspond to the amino acids of SEQ ID NO:
• 1;
• iii. position 3 of the analog is optionally an amino acid other than Asp, wherein the amino acid other than Asp confers relative resistance to DPP-IV mediated cleavage;
• iv. position 5 of the analog is optionally an amino acid other than Ser;
• v. position 8 of the analog is optionally an amino acid other than Asp;
• vi. position 10 of the analog is optionally an amino acid other than Met;
• vii. position 16 of the analog is optionally an amino acid other than Asn;
• viii. position 24 of the analog is optionally an amino acid other than Asn;
• ix. position 28 of the analog is optionally an amino acid other than Gln;
• and
• b) delivering the analog to the large intestine of the subject in an amount effective to ameliorate the condition.

A kit for use in treating a subject having, or at risk of developing, a condition in which functioning of the large intestine is impaired to enhance functioning of the large intestine comprising:

• a) a lyophilized formulation of a GLP-2 analog of SEQ ID NO:
• 1 comprising intestinotrophic activity, wherein
• i. position 2 of the analog is an amino acid other than Ala;
• ii. positions 1, 4, 6, 7, 9, 12-15, 17-23, 25-27, and 29-33 of the analog correspond to amino acids of SEQ ID NO:
• 1;
• iii. position 3 of the analog of SEQ ID NO:
• 1 is optionally an amino acid other than Asp, wherein the amino acid other than Asp confers relative resistance to DPP-IV mediated cleavage,
• iv. position 5 of the analog is optionally an amino acid other than Ser;
• v. position 8 of the analog is optionally an amino acid other than Asp;
• vi. position 10 of the analog is optionally an amino acid other than Met;
• vii. position 16 of the analog is optionally an amino acid other than Asn;
• viii. position 24 of the analog is optionally an amino acid other than Asn;
• ix. position 28 of the analog is optionally an amino acid other than Gln;
• b) a vial of sterile water for reconstitution;
• and
• c) instructions directing reconstitution.